RecruitingPhase 2NCT06088979
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease
Sponsor
Tourmaline Bio, Inc.
Enrollment
81 participants
Start Date
Feb 19, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- Clinical diagnosis of Graves' disease associated with moderate to severe active TED
- Onset of active TED symptoms within approximately 15 months
- Proptosis (exophthalmos) ≥3 mm above the normal range per investigator judgment (based upon race and gender) for the study eye
- CAS ≥4 (on the 7-item scale) for the study eye
- Presence of TSI \>130% of the normal reference standard or \>0.55 IU/L (depending on assay method) and laboratory reference ranges
Exclusion Criteria7
- Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision
- Any previous treatment with teprotumumab or other agent that inhibits the IGF-1 receptor
- History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to \>1 g of methylprednisolone for the treatment of TED. Previous oral steroid use with a cumulative dose of ≤1g methylprednisolone (or equivalent dosage for other systemic corticosteroid) for the treatment of TED, however, is allowed if the corticosteroid was discontinued at least 6 weeks before baseline (Day 1) and completely tapered by Baseline (if applicable).
- Systemic (oral or IV) corticosteroid use for conditions other than TED within 6 weeks of baseline (Day 1) or not completely tapered by baseline (if applicable).
- Any major illness/condition or evidence of an unstable clinical condition that, in the investigator's judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study
- Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participant's participation in the study
- Pregnant or lactating
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTOUR006 - 20 MG
TOUR006 20 MG
OTHERPlacebo
Placebo
DRUGTOUR006 - 50 MG
TOUR006 - 50 MG
Locations(56)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06088979
Related Trials
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT0640104429 locations
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
NCT050120331 location
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
NCT074230131 location
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
NCT071132621 location
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
NCT061123402 locations